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Objective: To investigate the characteristics of nursing home residents with psychosis and 
the association with potential underlying factors, such as pain, sleep disturbances, and 
antipsychotic medication. 
Method: 545 residents with and without dementia from 67 Norwegian nursing home units 
were included in the cross sectional analyses. Psychosis was the main outcome measure in 
our study; other outcome measures include quality of life (QoL), ADL function, cognitive 
function, pain, and antipsychotic medication. 
Results: 112 residents had one or more symptoms of psychosis, and compared to residents 
without psychosis, they had lower QoL (p <0.001), ADL function (p = 0.003) and cognitive 
functioning (p = 0.001). Adjusted logistic regression analyses showed that psychosis was 
associated with the prevalence of pain (OR: 3.19, 95% CI: 1.94-5.24), sleep disturbances (OR: 
4.51, 95% CI: 2.91-6.99), and total number of medication (OR: 1.10, 95% CI: 1.03-1.17). 
Residents with psychosis but without antipsychotic medication, had better quality of life (p = 
0.005) compared with residents receiving any antipsychotics. 
Conclusion: Psychosis in NH residents is associated with pain, sleep disturbances and number 
of medications. Residents with psychosis have poor quality of life, though better quality of 
life was observed among those who did not use antipsychotic medication. 
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Key Points:  
• Symptoms of psychosis are common in a nursing home population 
• Nursing Home residents with symptoms of psychosis had lower Quality of Life, ADL 
and cognitive function 
• Pain, sleep disturbances and number of drugs prescribed were associated to 
psychosis, and should be evaluated when making treatment decisions for symptoms 
of psychosis. 
Background: 
In an increasingly older population, more people are in need of institutional care, and in 
Norway, almost 50% of all deaths occurs in a nursing home (NH).1 These individuals are 
characterized by complex care needs, multiple acute and chronic conditions, and over 80% 
have dementia.2 Neuropsychiatric symptoms (NPS) such as agitation, psychosis and 
depression are often related to dementia, and over 90% experience at least one such 
symptom during the course of the disease.3,4 Symptoms of psychosis such as delusion and 
hallucinations are frequent, and the prevalence of delusion and hallucinations in a NH 
population vary between 14-33%, and 5-27% respectively.2,5-7 Along with neuropsychiatric 
symptoms, pain is frequent in NHs and between 30-60% of residents experience pain on a 
daily basis.8-10   
Psychosis symptoms can be distressing for residents, families, and carers alike, increases the 
risk of admission to a health care institution, and is associated with poor Quality of Life 
(QoL).11-14 In older residents, symptoms of psychosis have a multifactorial aetiology, and are 
often a result of delirium or dementia.15 In 2016 Helvik et al. found that psychosis in NH 
residents was associated with poor activities of daily living (ADL) functioning, and dementia 
severity.3 In 2012 Tosato et al. found an association between delusion and pain in a 
European NH population.16 The association between psychosis and pain was further studied 
by Habiger et al., who found that symptoms of psychosis such as delusion were ameliorated 
in residents receiving pain treatment.17  
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Recent guidelines on the treatment of neuropsychiatric symptoms in people with dementia, 
recommend the use of non-pharmacological interventions as a first-line approach.18,19 For 
psychosis symptoms that are not in an acute phase, these guidelines highlight the 
importance of identifying and treating possible underlying causes when deciding on 
treatment options for NPS.18,19 However, the treatment of psychosis is complex, and the 
medication of choice for psychosis symptoms is often antipsychotics such as haloperidol and 
risperidone, which are also known for harmful side effects such as accelerated cognitive 
decline and cerebrovascular events,  in this vulnerable population.20-22 Psychotropic drugs in 
NHs are frequently prescribed, and in 2016, Gulla et al. found that 73% of Norwegian NH 
residents used at least one psychotropic drug, but only 14% of the residents used 
antipsychotic medication.23 Janus et al. found that the antipsychotic prescription rate in 
Western European NHs ranges from 12% to as high as 59% in some countries.24  
The aim of this study is to explore the characteristics of NH residents with psychosis and to 
investigate whether residents with psychosis using antipsychotic medication differ from 
those not using antipsychotic medication. We aim to investigate possible underlying factors 
associated with symptoms of psychosis and hypothesize that these symptoms are associated 
with poor QoL, cognitive function, and ADL function. We also hypothesize that there are few 
clinical differences between residents with psychosis with and without antipsychotic drug 
prescription.  
Method: 
This study is based on baseline data from the COSMOS study. COSMOS is an acronym and 
stands for COmmunication, Systematic assessment and treatment of pain, Medication 
review, Occupational therapy and Safety. The study protocol was published by Husebo et al. 
in 2015, and is fully described elsewhere.25 
The study was conducted from 2014 to 2015 and included 545 residents from 67 NH units, in 
both western and eastern Norway. The COSMOS study is a cluster randomized controlled 
trial (RCT), investigating the effect of the implementation of a complex intervention with 
focus on the four key COSMOS subjects lasting for 4 months and followed up at month 9. 
Inclusion criteria were NH residents ≥65 years old, with and without dementia. Residents 
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with a life expectancy ≤6 months or residents with schizophrenia were excluded from the 
study. The data in this article is based on the baseline data collection. 
Outcome measures: 
The primary measure for assessment of psychosis was the Neuropsychiatric Inventory 
Nursing Home version (NPI-NH), which was developed by Cummings et al. 26, translated into 
Norwegian and thoroughly tested for reliability and validity by Selbaek et al..27 The NPI-NH 
assesses 12 different NPS such as delusion, hallucinations, depression and sleep 
disturbances, and assesses the frequency (F) and severity (S) of each symptom. Frequency is 
measured on a scale from 0–4, where 0 represents not present and 4 represents symptom 
present on a daily basis. Severity is measured on a scale from 1–3, where 1 represents mild 
severity with little stress for the resident, and 3 represents a severe symptom with much 
stress on the resident. The frequency and severity score are then multiplied together to 
generate a total score for each symptom (FxS) ranging from 0-12. A resident was defined as 
having an NPS, when he had an FxS score ≥4, as this is deemed a clinically significant score.28 
The different symptoms can be clustered together in various ways, and symptom clusters 
contain the NPS that are closely related in the clinical setting, such as depression and anxiety 
in a mood cluster, agitation and irritability in an agitation cluster, and delusion and 
hallucination in a psychosis cluster.29-31 The psychosis cluster in our study includes both 
hallucinations and delusion, and residents were classified as having psychosis if they had an 
FxS score ≥4 on either one or both of these symptoms. Sleep disturbances and appetite 
disturbances were assessed using their respective items on the NPI-NH. 
For investigation of associations with psychosis, we included assessment tools for cognitive 
function, depression, QoL, behavioral disturbances, activities of daily living (ADL) function 
and pain. Cognitive performance was assessed using the Mini Mental State Exam (MMSE) 
generating a score from 0 to 30, where a low score indicates poor cognitive function.32 The 
category Activities of daily living was assessed using the Lawton and Brody’s ADL assessment 
tool, generating a score from 0 to 30, where higher scores indicate lower functional 
independence.33 Depression was assessed using the Cornell Scale for Depression in 
Dementia (CSDD) generating a score of 0–38, where a high score indicates a severe degree 
of depression.34 QoL was assessed using the 18-item version of Quality of life in dementia 
(QUALIDEM) generating a score from 0 to 54 where a low score indicates poor QoL while a 
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high score indicates a high QoL.35 QoL was also assessed using Quality of life in late stages of 
Dementia (QUALID), generating a score from 11 to 55 where a high score indicates poor 
QoL.36 Behavioral disturbances were evaluated by the Cohen-Mansfield Agitation Inventory 
(CMAI) generating a score from 29 to 203, where a high score indicates a high level of 
behavioral disturbance.37 Pain was evaluated by the Mobilisation – Observation – Behavioral 
- Intensity - 2 Pain Scale (MOBID-2) which assesses pain related to the musculoskeletal 
system, internal organs, head and skin, and generates a score from 0–10, where 0 indicates 
no pain, and 10 indicates the highest pain possible.38,39 Information about diagnoses and 
medication were obtained from the residents’ medical records. Psychotropic drugs were 
defined as the group noted N05 in the Anatomical Therapeutic Chemical (ATC) register. 
Psychotropic drugs were also divided into the subgroups antipsychotics (N05A), anxiolytics 
(N05B) and hypnotics and sedatives (N05C) in line with ATC register. The MMSE were 
performed by one of four full-time researchers in the COSMOS team consisting of one 
physician, one nurse and two medical students. All other assessments were performed by a 
caregiver who knew the resident well, after receiving training from the COSMOS team on 
using the different assessment tools. 
Statistics 
To test differences in characteristics between residents with and without clinically significant 
psychosis symptoms, independent sample t-test were used for normally distributed 
variables; a chi-squared test was used for categorical variables and Mann Whitney U-test for 
non-normally distributed variables. To test associations between symptoms of psychosis and 
other factors (ADL function, pain, depression, medication, QoL, nighttime disturbances and 
appetite disturbances as measured with the NPI-NH), logistic regression with robust 
standard error estimation adjusting for clustered design was used. Odds Ratios were 
calculated for each factor and adjusted for age, gender, dementia diagnosis and cognitive 
functioning. Statistical analyses were performed using IBMs Statistical Package for Social 
Sciences (SPSS) version 23 and StataCorps Stata version 15.0. 
Ethics: 
Verbal and written informed consent was obtained from residents who were cognitively able 
to understand the information regarding the COSMOS study. In residents lacking the ability 
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to consent, a verbal and written presumed consent was obtained, after explaining the study 
procedure, from the residents’ next of kin or legal guardian, with the resident present if 
possible. The trial was approved by the Regional Committee for Medical and Health 
Research Ethics, West Norway (REK 2013/1765), and registered at clinicaltrials.gov 
(NCT02238652). 
Results: 
Five hundred and forty-five residents from 67 NH units were included in the study; 33 
residents had incomplete data for the NPI-NH assessment of psychosis symptoms, resulting 
in 512 participants in the final analyses. The mean age was 87 years, and 73% were women 
(Table 1). One-hundred and twelve residents (21.9%) had one or more symptoms of 
psychosis, 94 (18.4%) had delusion, and 45 (8.8%) had hallucinations. Compared to residents 
without psychosis, those with psychosis more often had dementia (p = 0.004, df: 510), 
poorer QoL on both the QUALIDEM (p <0.001, df: 502) and QUALID (p <0.001, df: 502) 
assessment tool, more behavioral disturbances (p <0.001, df: 493) and lower ADL function (p 
= 0.003, df: 505). (Table 1) Residents with psychosis also had higher depression scores 
assessed by CSDD (p <0.001, df: 415), more sleep disturbances (X2 = 47.7, p <0.001), poorer 
cognitive function on the MMSE (p = 0.001, df: 472) and more pain (p = 0.002, df: 438) (Table 
1). More psychotropic drugs were prescribed to residents with psychosis (p = 0.015, df = 
503), without differences between antipsychotics, anxiolytics and hypnotics and sedatives 
(Table 1 & Figure 1). Residents with psychosis using no antipsychotic medication, had better 
QoL on the QUALIDEM (p = 0.005, df = 108) and lower total scores on the NPI-NH (p = 0.035, 
df = 108) compared to those treated with antipsychotic medication. Residents with psychosis 
using antipsychotic medication did not differ from residents using no antipsychotic 
medication in ADL function, pain and cognitive function. (Figure 2) 
In the logistic regression analyses with adjustment for clustered design, age, sex, dementia 
diagnose and cognitive function, psychosis was found to be associated with poor QoL 
(adjusted Odds Ratio: 0.89, 95% CI: 0.86-0.92, p <0.001), depression (aOR: 1.21, 95% CI: 
1.15-1.27, p <0.001), number of prescribed drugs (aOR: 1.10, 95% CI: 1.03-1.17, p = 0.005), 
nighttime disturbances (aOR: 4.51, 95% CI: 2.91-6.99, p <0.001), appetite disturbances (aOR: 
3.46, 95% CI: 1.65-7.27, p = 0.001) and pain (aOR: 3.19, 95% CI: 1.94-5.24, p <0.001). The 
same associations were found for the individual symptoms of delusion and hallucinations, 
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with the exception of an association between hallucinations and ADL function (aOR: 1.19, 
95% CI: 1.07-1.33, p = 0.773) (Table 2). Psychosis symptoms were found to be associated 
with all other NPS measured with the NPI (Table 2). The same associations were found for 
the individual symptom delusion, while hallucinations were found to not be associated with 
apathy (aOR: 2.02, 95% CI: 0.91 – 4.48, p = 0.082), disinhibition (aOR: 1.37, 95% CI: 0.56 – 




The study showed that NH residents with psychosis had poorer QoL compared to residents 
without psychosis, and that residents with psychosis not using any antipsychotic medication 
had better QoL compared to residents not using antipsychotics. Psychosis was found to be 
associated with pain, number of drugs prescribed, sleep disturbances, appetite disturbances 
and depression. The findings are important for the clinician because they highlight the 
detrimental impact that symptoms of psychosis have on NH residents, the importance of 
treating the symptoms and possible underlying causes, and the complexity of such 
treatment. 
Our study is one of the largest studies focusing on psychosis in NH residents, and adds 
important knowledge about psychosis in NH residents. The findings regarding psychosis and 
QoL are in line with previous studies where psychosis was found to have a negative impact 
on QoL. Mjorud et al. investigated variables associated with QoL in Norwegian NH residents 
with dementia, and found an association between poor QoL and psychosis,14 while Wetzels 
et al. studied determinants of QoL in Dutch NH residents with dementia and found that 
psychosis was associated to lower QoL.13  As in our study, the NPI-NH was used to measure 
psychosis, making the studies comparable.  The association between psychosis and sleep 
disturbances is an important finding.  Previous studies on psychosis and sleep disturbances 
have found an association between psychosis and insomnias. 40,41 These studies, however, 
were only performed on patients aged 16–74 years, and there is a lack of studies on the 
association between psychosis and sleep disturbances in patients aged 75 years and older. 
Sleep disturbances in our study are also a more broad term as it includes all types of sleep 
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disturbances, not only insomnia. It is also important to note that a recent study by Blytt et al. 
found a large discrepancy between the NPI-NH item sleep disturbances and objectively 
measured sleep disturbances with actigraphy.42 Since our results are cross-sectional, we 
cannot claim causality, so there is a need for further studies, and the use of a more reliable 
measure of sleep disturbances may be warranted in the future.  
A previous study by Helvik et al. on the severity of NPS in 2898 Norwegian NH residents, 
found an association between psychosis severity and ADL function.3 Though residents with 
psychosis had lower ADL function than residents without psychosis in our study, no 
significant association was found between psychosis and ADL function when adjusting for 
confounding factors such as age, and cognitive function. A reason for this difference could 
be that the two symptoms of psychosis impact ADL function in different ways. This is 
supported by our results, as hallucinations were found to be associated with poor ADL 
function when adjusting for confounding factors, while no such association was found for 
delusion. It is also worth noting that Helvik et al. investigated the association between 
psychosis severity and ADL function, and not between ADL function and the presence of 
psychosis as in our study.   
The finding that NH residents with psychosis using any antipsychotic medication had poorer 
QoL when compared to residents with psychosis using no antipsychotics highlights a 
challenge in treating psychosis in NH residents. Antipsychotic medication may be necessary 
in the acute setting where the resident can cause harm to himself and others, but the use of 
antipsychotics in treatment of psychosis in a chronic phase is a more complex matter.  
Guidelines state that non-pharmacological options such as environmental and psychosocial 
measures should be first-line treatment for psychosis in a chronic phase before 
antipsychotics are used, but few concrete suggestions are made.19 Knowledge about the 
effect of non-pharmacological measures on psychosis is scant, and few studies have been 
performed.43 In a study conducted by Chen et al. in 2014, it was found that delusions and 
hallucinations in 104 older Taiwanese men with dementia were reduced in response to an 
organized program of non-pharmacological measures.44 The number of patients was low, 
however, and the study only included men.44 Arguments can be made that residents using 
antipsychotic medication have a more severe degree of psychosis than residents not using 
antipsychotics do. However, this does not seem to be the case in our study as there were no 
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significant difference in the total NPI-NH score of psychosis for residents with psychosis 
using any antipsychotic medication and those who did not use any antipsychotic medication 
(Figure 2). When interpreting the results regarding antipsychotic medication, it is important 
to have some limitations mind. Residents with psychosis experienced more behavioral 
disturbances such as aggression, than residents without psychosis. The use of antipsychotic 
medication such as Risperidone, and in some cases Haloperidol in delirious residents, are 
recommended in treating aggression, and there is a possibility that some of the use of 
antipsychotic medication in the psychosis group are due to aggression and not psychosis. 
The number of antipsychotic medication used in order to treat psychosis may therefore be 
lower than the total number of antipsychotics prescribed in residents with psychosis 
symptoms. One also has to take into consideration the somewhat low number of residents 
and the design of the study, but the findings are an important stepping-stone for future 
studies. The efficacy of non-pharmacologically treatment approaches to psychosis is a key 
point that needs further investigations. 
We also found that the total number of drugs was associated with symptoms of psychosis. 
Polypharmacy is a well-known challenge in NH residents and increases the risk of hospital 
admission, circulatory and endocrine co-morbidity and neurological motor dysfunction.45 
The number of drugs also increases the possibility of anti-cholinergic side effects, such as 
confusion and delirium.46 Delirium is often hard to distinguish from psychosis and has many 
of the same symptoms such as delusion and hallucinations.15 Our findings support the 
hypothesis that psychosis is associated with polypharmacy, and they highlight the 
importance of a thorough medication review by physicians so as to avoid unnecessary drug 
prescription and development of possible debilitating side effects. 
The association between pain and psychosis is supported to a certain degree by previous 
studies. Tosato etal. found an association between pain and delusion in NH residents with 
cognitive impairment; however, they did not find an association between pain and 
hallucinations.16 An explanation for this is perhaps the use of different assessment tools for 
psychosis symptoms, as the NPI-NH is more suited to detect and differentiate between 
psychosis symptoms than the minimum dataset residents assessment instrument. Our own 
findings suggest that symptoms of psychosis, especially delusions, were ameliorated in 
response to pain treatment in residents with behavioral disturbances and dementia.17 In 
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contrast to the present study, we did not find a cross-sectional association between pain and 
symptoms of psychosis. A reason for this may be the more selected group of residents in the 
2016 study, as it consisted of NH residents with dementia and behavioral disturbances. Our 
findings have clinical importance in that they indicate the need for a thorough pain 
assessment before making treatment decisions for residents with psychosis. If psychosis is 
caused, or triggered, by an underlying treatable factor such as pain, then treatment of this 
factor can ameliorate the symptoms of psychosis without the need for antipsychotic 
medication. Pain as a cause for NPS can be treated using a stepwise protocol for treating 
pain or a multidisciplinary approach, which has shown an effect in previous studies.47-49 Our 
findings are cross-sectional, however, and there is a need to look at the association of pain 
and psychosis over time to gain more solid knowledge.  
Strengths and Limitations: 
One of the strengths of this study is the broad inclusion criteria where all NH residents ≥65 
years of age, a life expectancy >6 months and without schizophrenia were included. The 
greatest limitation lies perhaps in the cross-sectional design of the study, which cannot 
differentiate properly between psychosis in an acute and chronic setting, and makes 
conclusions on causality difficult. More longitudinal studies are needed to draw conclusions 
on causality. Another limitation regarding the design of the study, is that it is based on 
secondary analysis from an already existing database, where power calculations were made 
on the basis of other assessment tools and designs than our study. Therefore there is a 
possibility that our study group may be underpowered.  As it is not clear-cut which 
symptoms are possible confounders, the regression analyses was not adjusted for the impact 
of other NPS. This is a limitation, which is important to keep in mind when interpreting the 
results. There is also a lack of information regarding the cause of psychosis in residents 
without dementia which is a limitation.  The assessment of many of the outcome measures 
were made by proxy-raters who knew the resident well. While studies have shown this to be 
an accurate assessment, especially for symptoms of psychosis, it cannot replace self-report 




Symptoms of psychosis in NH residents lead to poorer QoL, more sleep disturbance, and are 
associated with pain and number of prescribed drugs. The use of antipsychotic medication in 
treatment of psychosis symptoms is associated with poorer QoL. The findings highlight that a 
thorough and broad evaluation of possible underlying causes should be made before making 
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Table 1: Characteristics of residents with and without psychosis 
 Psychosis  
(n = 112)  
Without psychosis 
(n = 400) 
p-value Total population  
(n = 512) 
Women (%) 87 (77,7) 292 (73,0) 0.318a 379 (74.0) 
Age (SD) 86,6 (7.5) 86,7 (7.4) 0.629b 86.9 (7.4) 
Dementia diagnosis (%) 86 (76.8) 248 (62.0) 0.004a 334 (65.2) 
MMSE score (SD) 9,0 (6.7) 11,8 (7.8) 0.001c 11.2 (7.7) 
ADL score (SD) 18,5 (5.6) 16,8 (5.1) 0.003c 17.1 (5.3) 
Cornell score (SD) 12,5 (7.2) 5,7 (5.0) <0.001c 7.1 (6.2) 
CMAI score (SD) 55,2 (18.7) 38,6 (11.8) <0.001c 42.3 (15.3) 
QUALID score (SD) 26,9 (8.3) 20,0 (6.5) <0.001c 21.5 (7.5) 
QALIDEM score (SD) 32.7 (8.8) 41.2 (8.1) <0.001b 39.2 (8.9) 
MOBID-2 score (SD) 3,2 (2.6) 2,3 (2.6) 0.002c 2.5 (2.6) 
NPI-NH total score (SD) 40,1 (23.3) 11,6 (14.0) <0.001b 17.8 (20.2) 
NPI-NH total carer strain 
(SD) 
15.4 (9.3) 4.8 (6.0) <0.001c 7.0 (8.1) 
Agitation/Aggression (%) 57 (50.9) 61 (15.3) <0.001a 118 (23.0) 
Depression (%) 53 (47.3) 66 (16.5) <0.001a 119 (23.2) 
Anxiety (%) 50 (44.6) 67 (16.8) <0.001a 117 (22.9) 
Euphoria (%) 8 (7.1) 12 (3.0) 0.044a 20 (3.9) 
Apathy (%) 26 (23.2) 47 (11.8) 0.002a 73 (14.3) 
Disinhibition (%) 33 (29.5) 48 (12.0) <0.001a 81 (15.8) 
Irritability (%) 74 (66.0) 87 (21.8) <0.001a 161 (31.4) 
Aber. motor behaviour (%) 28 (25.0) 30 (7.5) <0.001a 58 (11.3) 
Appetite disturbances (%) 20 (17.9) 25 (6.3) <0.001a 45 (8.8) 
Sleep Disturbances (%) 46 (41.0) 61 (15.3) <0.001a 107 (20.9) 
Drugs as prescribed (SD) 8,4 (3.7) 7,9 (3.8) 0.226c 8.0 (3.8) 
Psychotropics (%)† 66 (58.9) 185 (46.3) 0.015a 251 (49.0) 
Antipsychotics (%) 20 (17.9) 57 (14.4) 0.333a 77 (15.0) 
Anxiolytics (%) 28 (25.0) 79 (19.8) 0.216a 107 (20.9) 
Hypnotic and Sedatives (%) 41 (36.6) 115 (28.8) 0.101a 156 (30.5) 
Analgesics (%) 74 (66.0) 227 (56.8) 0.064a 301 (58.8) 
Antidepressants (%) 46 (41.1) 163 (40.8) 0.951a 209 (40.8) 
Antidementia drugs (%) 24 (20.8) 55 (13.8) 0.047a 79 (15.4) 
Anti-Parkinson drugs (%) 6 (5.4) 21 (5.3) 0.964a 27 (5.3) 
Drugs as needed (SD) 4.0 (2.0) 3.2 (2.2) <0.001c 3.4 (2.2) 
Psychotropics (%)† 90 (80.4) 230 (57.5) <0.001a 320 (62.5) 
Antipsychotics (%) 8 (7.1) 21 (5.3) 0.444a 29 (5.7) 
Anxiolytics (%) 73 (65.2) 172 (43.0) <0.001a 245 (47.9) 
Hypnotic and Sedatives (%) 42 (37.5) 99 (24.8) 0.008a 141 (27.5) 
Analgesics (%) 93 (83.0) 289 (72.3) 0.020a 382 (74.6) 
Notes: MMSE indicates Mini Mental State Exam; ADL, Activities of Daily Living; CMAI, Cohen Mansfield 
Agitation Inventory; QUALID, Quality of Life in late-stage Dementia; QUALIDEM, Quality of Life in Dementia; 
MOBID-2, Mobilization-Observation-Behavior-Intensity-Dementia-2 pain scale; NPI-NH. Neuropsychiatric 
Inventory Nursing Home version 
aChi Squared test 
bIndependent t-test samples 
cMann-Whitney U-test 






Table 2: Symptoms of Psychosis and associated features 
Psychosis OR (95% CI) p-valuea 
Pain (MOBID2 ≥3) 3.19 (1.94 – 5.24) <0.001 
ADL function 1.03 (0.98 – 1.09) 0.213 
Quality of life (QUALIDEM) 0.89 (0.86 – 0.92) <0.001 
Depression (CSDD) 1.21 (1.15 – 1.27) <0.001 
Number of prescribed drugs 1.10 (1.03 – 1.17) 0.005 
Sleep disturbances 4.51 (2.91 – 6.99) <0.001 
Appetite disturbance 3.46 (1.65 – 7.27) 0.001 
Agitation/Aggression 5.37 (3.21 – 8.97) <0.001 
Depression (NPI-NH) 4.49 (2.73 – 7.37) <0.001 
Anxiety 4.60 (2.67 – 7.93) <0.001 
Apathy 2.27 (1.38 – 3.73) 0.001 
Disinhibition 2.65 (1.45 – 4.83( 0.001 
Aberrant Motor Behaviour 3.51 (1.72 – 7.17) 0.001 
Euphoria 3.30 (1.39 – 7.85) 0.007 
Irtitability 6.27 (3.95 – 9.96) <0.001 
Delusion 
Pain (MOBID2 ≥3) 2.89 (1.75 – 4.76) <0.001 
ADL function 1.01 (0.95 – 1.07) 0.773 
Quality of life (QALIDEM) 0.89 (0.86 – 0.92) <0.001 
Depression (CSDD) 1.22 (1.17 – 1.28) <0.001 
Number of prescribed drugs 1.11 (1.04 – 1.20) 0.003 
Sleep disturbances 4.06 (2.57 – 6.42) <0.001 
Appetite disturbance 3.13 (1.49 – 6.55) 0.003 
Agitation/Aggression 5.47 (3.06 – 9.81) <0.001 
Depression (NPI-NH) 4.29 (2.56 – 7.20) <0.001 
Anxiety 4.28 (2.47 – 7.42) <0.001 
Apathy 2.17 (1.27 – 3.69) 0.004 
Disinhibition 3.03 (1.70 – 5.39) <0.001 
Aberrant Motor Behaviour 3.02 (1.51 – 6.05) 0.002 
Euphoria 4.03 (1.69 – 9.65) 0.002 
Irtitability 6.41 (3.87 – 10.61) <0.001 
Hallucinations 
Pain (MOBID2 ≥3) 2.78 (1.23 – 6.28) 0.014 
ADL function 1.19 (1.07 – 1.33) 0.001 
Quality of life (QALIDEM) 0.88 (0.84 – 0.93) <0.001 
Depression (CSDD) 1.15 (1.09 – 1.22) <0.001 
Number of prescribed drugs 1.09 (1.01 – 1.18) 0.029 
Sleep disturbances 5.02 (2.55 – 9.90) <0.001 
Appetite disturbance 4.33 (1.87 – 10.02) 0.001 
Agitation/Aggression 3.67 (1.90 – 7.11) <0.001 
Depression 2.91 (1.36 – 6.22) 0.006 
Anxiety 4.17 (2.05 – 8.48) <0.001 
Apathy 2.02 (0.91 – 4.48) 0.082 
Disinhibition 1.37 (0.56 – 3.31) 0.490 
Aberrant Motor Behaviour 3.32 (1.61 – 6.84) 0.001 
Euphoria 1.40 (0.30 – 6.57) 0.668 
Irtitability 2.56 (1.29 – 5.08) 0.007 
Notes: MOBID2 indicates Mobilization-Observation-Behavior-Intensity-Dementia-2 pain scale; ADL, Activities 
of Daily Living; QUALIDEM, Quality of Life in Dementia; CSDD, Cornell Scale of Depression in Dementia 





Figure 1: Psychotropic drug prescription in residents with and without psychosis 
 
Figure 2: Residents with psychosis using antipsychotics compared to residents with 
psychosis using no antipsychotics 
 
 
